Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

NanoDeliveryEnhance

Financiado

Novel functionalization of liposomic nano-vehicles for strongly-enhanced drug de...

Delivery to diseased cells or tissues of therapeutic agents attached or encapsulated in nanoparticles – nanomedicine - presents many benefits, and comprises a rapidly-growing multi-billion-euro market. Lipid-based drug-delivery na... ver más

31/07/2024

WEIZMANN

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 1 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-07-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

WEIZMANN

150.00K€ | Lider

Proyectos interesantes

OatLive Mix and Match: One-step activation for targeted drug deliver... 150K€ Cerrado

FluoNeeD Fluorinated Lipid Nanoparticles for Gene Delivery and Diagno... 212K€ Cerrado

BiofilmEradicate Modification of liposomic nano-carriers: a novel strategy fo... 150K€ Cerrado

SAF2010-15547 NANOSISTEMAS PARA LA ADMINISTRACION ORAL DE AGENTES ANTITUMO... 145K€ Cerrado

RTI2018-101309-B-C21 SINTESIS Y CARACTERIZACION DE NANOGHOSTS COMO SISTEMAS NOVED... 154K€ Cerrado

PID2021-122187NB-C31 FORMULACION DE NUEVOS NANOPORTADORES NO LIPIDICOS CRISTALINO... 145K€ Cerrado

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2023-01-26
Fecha Fin: 2024-07-31

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Delivery to diseased cells or tissues of therapeutic agents attached or encapsulated in nanoparticles – nanomedicine - presents many benefits, and comprises a rapidly-growing multi-billion-euro market. Lipid-based drug-delivery nano-vehicles, where drugs (not least the recent, very-widely-used, mRNA-based COVID-19 vaccines) are encapsulated in lipid vesicles (liposomes) or lipid nanoparticles, form a substantial part of that market. Nearly all FDA-approved liposomic vehicles are functionalized with poly(ethylene glycol), PEG, moieties, the current gold-standard. These act both to sterically-stabilize the vesicles, and, importantly, increase their blood-retention time and thus their therapeutic efficiency. At the same time, such PEGylation has several drawbacks, including reduced cellular uptake, accumulation of PEG in tissues, and accelerated blood clearance on repeated intravenous dosage due to heightened immune response. We use novel functionalization approaches to overcome these drawbacks. The present project explores the innovation dimension of our new approach. In particular, is it effective? is it efficient? How widely applicable is it? What is the IPR position for future exploitation of this new strategy? These questions illustrate the high-risk/high-gain nature of this proposal, and are addressed here through several inter-related work packages. Success of our project in demonstrating that our novel approach is significantly superior to the current universally-used PEGylation would not only have a therapeutic advantage for many diseases, but also tap into a large and growing market.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores